Abdulrafeh Naqash to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Antineoplastic Agents, Immunological.
Connection Strength
3.993
-
Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022 10 10; 40(29):3439-3452.
Score: 0.781
-
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 Jul; 69(7):1177-1187.
Score: 0.669
-
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer. 2019 07 05; 7(1):169.
Score: 0.638
-
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019 01 08; 7(1):4.
Score: 0.617
-
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database. Acta Oncol. 2018 06; 57(6):867-872.
Score: 0.573
-
Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. Acta Oncol. 2017 10; 56(10):1327-1330.
Score: 0.550
-
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583.
Score: 0.164